

Certificate of Analysis

SAPK4, active

(Recombinant enzyme expressed in *E.coli* cells)

Item # 14-249-K

Lot # D8EN044U

Product Description: N-terminal GST tagged, full length human SAPK4 expressed in *E.coli* cells. Purified using glutathione sepharose. Activated using a constitutively active mutant of MKK6 and repurified using glutathione sepharose. Purity 99% by SDS-PAGE and Coomassie blue staining. MW = 68.9kDa.

Formulation: 3.127mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 50% glycerol, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Liquid at -20°C.

Specific Activity (lot# D8EN044U): 252U/mg, where one unit of SAPK4 activity is defined as 1nmol phosphate incorporated into 0.33mg/ml MBP per minute at 30°C with a final ATP concentration of 100µM.



Storage and Stability: Stable for 1 year at -20°C from date of shipment. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 8.44–106ng of this lot of enzyme phosphorylated 0.33mg/ml MBP in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.

MS Tryptic Fingerprint: Confirmed identity as SAPK4 with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 125mM Tris/HCl pH7.5, 0.1mM EGTA.
2. **Myelin Basic Protein (MBP):** Use at a final concentration of 0.33mg/ml. Prepare a 3.33mg/ml stock. Use 2.5µl of stock per assay point.
3. **SAPK4, active:** Dilute with 50mM Tris/HCl pH7.5, 0.1mM EGTA, 0.1mM Na₃VO₄, 0.1% 2-mercaptoethanol. Use 8.44–106ng per assay point.
4. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl 5 x reaction buffer to wells.
2. Add 2.5µl of **MBP**.
3. Add **2.5µl (8.44–106ng) SAPK4, active**.
4. Add 5µl of dH₂O.
5. Add 10µl of diluted [γ-³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat twice for 5 minutes with 75mM phosphoric acid.
10. Wash filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

SAPK4 Sequence Information

<u>Protein</u>	Human SAPK4
<u>Tags</u>	N-terminal GST
<u>Native sequence</u>	M230 of the recombinant protein is equivalent to M1 of human SAPK4
<u>Accession number</u>	EMBL Y10488

Recombinant SAPK4 amino acid sequence:

```

1 MSPILGYWKI KGLVQPTRL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLP EML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSPEFM SLIRKKGFYK
241 QDVNKTAWEL PKTYVSPTHV GSGAYGSVCS AIDKRSGEKV AIKKLSRPFQ SEIFAKRAYR
301 ELLLLLKHMQH ENVIGLLDVF TPASSLRNFY DFYLVMPFMQ TDLQKIMGME FSEEKIQYLV
361 YQMLKGLKYI HSAGVVHRDL KPGNLAVNED CELKILDFGL ARHADAEMTG YVVTRWYRAP
421 EVILSWMHYN QTVDIWSVGC IMAEMLTGKT LFKGKDYLDQ LTQILKVTGV PGTEFVQKLN
481 DKAASKSYIQS LPQTPRKDFT QLFPRASPQA ADLLEKMLEL DVDKRLTAAQ ALTHPFFPEFP
541 RDPEEETEAQ QPFDDSL EHE KLTVDEWKQH IYKEIVNFSP IARKDSRRRS GMKL

```

Recombinant SAPK4 nucleotide sequence:

```

1 atgtccccta tactaggtta ttgaaaatt aagggccttg tgcaaccac tcgacttctt
61 ttggaatata ttgaagaaaa atatgaagag catttgatg agcgcgatga aggtgataaa
121 tggcgaacaa aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat
181 ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac
241 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg
301 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt
361 gattttctta gcaagctacc tgaaatgctg aaaatggtcg aagatcgttt atgtcataaa
421 acatatttaa atggtgatca tgtaaccat cctgacttca tgttgatga cgctcttgat
481 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
601 tggcctttgc agggctggca agccacgtt ggtggtggcg accatcctcc aaaatcggat
661 ctggttccgc gtggatcccc ggaattcatg agcctcatcc ggaaaaaggg cttctacaag
721 caggacgtca acaagacagc ctgggagctg cccaagacct acgtgtcccc gacgcacgtc
781 ggacagcggg cctatggctc cgtgtgctcg gccatcgaca agcggtcagg ggagaagggtg
841 gccatcaaga agctgagccg accctttcag tccgagatct tcgccaagcg cgcctaccgg
901 gagctgctgc tgctgaagca catgcagcat gagaacgtca ttgggctcct ggatgtcttc
961 acccagcct cctccctgcg caacttctat gacttctacc tgggtgatgcc cttcatgcag
1021 acggatctgc agaagatcat ggggatggag ttcagtgagg agaagatcca gtacctggtg
1081 tatcagatgc tcaaaggcct taagtacatc cactctgctg gggctcgtgca cagggacctg
1141 aagccaggca acctggctgt gaatgaggac tgtgaactga agattctgga ttttgggctg
1201 gcgcgacatg cagacccga gatgactggc tacgtggtga cccgctggta ccgagcccc
1261 gaggtgatcc tcagctggat gcactacaac cagacagtgg acatctggtc tgtgggctgt
1321 atcatggcag agatgctgac agggaaaact ctgttcaagg ggaaagatta cctggaccag
1381 ctgaccaga tcctgaaagt gaccggggtg cctggcacgg agtttgtgca gaagctgaac
1441 gacaaagcgg ccaaatccta catccagtcc ctgccacaga ccccaggaa ggatttact
1501 cagctgttcc cacggccag ccccaggct gcggacctgc tggagaagat gctggagcta
1561 gacgtggaca agcgcctgac ggccgcgac gccctcacc atcccttctt tgaaccctt

```

Certificate of Analysis

```
1621 cgggaccctg aggaagagac ggaggcccag cagccgtttg atgattcctt agaacacgag
1681 aaactcacag tggatgaatg gaagcagcac atctacaagg agattgtgaa cttcagcccc
1741 attgcccgga aggactcacg gcgccggagt ggcatgaagc tgtag
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services